What's new
By:
Filters
Cystic Fibrosis Forum (EXP)

This is a sample guest message. Register a free account today to become a member! Once signed in, you'll be able to participate on this site by adding your own topics and posts, as well as connect with other members through your own private inbox!

Have a Read

B

Brad

New member
I Hope this link works..

A lot of You may get these same E mails from CFF.
Check out the 2 videos on the Cf Cillia and Non Cf.


<a target=_blank class=ftalternatingbarlinklarge href="http://www.cff.org/aboutCFFoundation/Publications/connections/june2009/BasicDefect.cfm">http://www.cff.org/aboutCFFoun...ne2009/BasicDefect.cfm</a>
 
B

Brad

New member
I Hope this link works..

A lot of You may get these same E mails from CFF.
Check out the 2 videos on the Cf Cillia and Non Cf.


<a target=_blank class=ftalternatingbarlinklarge href="http://www.cff.org/aboutCFFoundation/Publications/connections/june2009/BasicDefect.cfm">http://www.cff.org/aboutCFFoun...ne2009/BasicDefect.cfm</a>
 
B

Brad

New member
I Hope this link works..

A lot of You may get these same E mails from CFF.
Check out the 2 videos on the Cf Cillia and Non Cf.


<a target=_blank class=ftalternatingbarlinklarge href="http://www.cff.org/aboutCFFoundation/Publications/connections/june2009/BasicDefect.cfm">http://www.cff.org/aboutCFFoun...ne2009/BasicDefect.cfm</a>
 
B

Brad

New member
I Hope this link works..

A lot of You may get these same E mails from CFF.
Check out the 2 videos on the Cf Cillia and Non Cf.


<a target=_blank class=ftalternatingbarlinklarge href="http://www.cff.org/aboutCFFoundation/Publications/connections/june2009/BasicDefect.cfm">http://www.cff.org/aboutCFFoun...ne2009/BasicDefect.cfm</a>
 
B

Brad

New member
I Hope this link works..
<br />
<br /> A lot of You may get these same E mails from CFF.
<br /> Check out the 2 videos on the Cf Cillia and Non Cf.
<br />
<br />
<br /> <a target=_blank class=ftalternatingbarlinklarge href="http://www.cff.org/aboutCFFoundation/Publications/connections/june2009/BasicDefect.cfm">http://www.cff.org/aboutCFFoun...ne2009/BasicDefect.cfm</a>
 
B

Brad

New member
This is the Part that really has me interested.

( She noted that experts never expected that patients with preexisting lung damage would see such drastic improvements when taking a drug like VX-770.)
 
B

Brad

New member
This is the Part that really has me interested.

( She noted that experts never expected that patients with preexisting lung damage would see such drastic improvements when taking a drug like VX-770.)
 
B

Brad

New member
This is the Part that really has me interested.

( She noted that experts never expected that patients with preexisting lung damage would see such drastic improvements when taking a drug like VX-770.)
 
B

Brad

New member
This is the Part that really has me interested.

( She noted that experts never expected that patients with preexisting lung damage would see such drastic improvements when taking a drug like VX-770.)
 
B

Brad

New member
This is the Part that really has me interested.
<br />
<br /> ( She noted that experts never expected that patients with preexisting lung damage would see such drastic improvements when taking a drug like VX-770.)
 
J

Jeana

New member
Actually, they are doing a clinical trial to see if it works on Delta F508, as well. Our clinic is participating.

According to the CFF website:

"VX-770, the most advanced of the two compounds, is known as a potentiator and is designed to allow CFTR located at the cell surface to function correctly.

Why wasn't the Delta F508 mutation chosen for the Phase 2 VX-770 clinical trials?

Because G551D is already located at the cell surface, these patients have the greatest potential to benefit from treatment with VX-770."

This means, that if the CFTR was located at the cell surface, it might work for Delta F508. So, if we use the VX-809 and the VX-770, Delta F508s might have very good results, since...

"Vertex is also developing VX-809, known as a corrector, which is designed to move defective CFTR to its proper place in the cell."

*In other words, VX-809 should move the CFTR to the cell surface and VX-770 should correct the CFTR at the cell surface.*

<a target=_blank class=ftalternatingbarlinklarge href="http://www.cff.org/research/ClinicalResearch/FAQs/VX-770/">http://www.cff.org/research/Cl...lResearch/FAQs/VX-770/</a>
 
J

Jeana

New member
Actually, they are doing a clinical trial to see if it works on Delta F508, as well. Our clinic is participating.

According to the CFF website:

"VX-770, the most advanced of the two compounds, is known as a potentiator and is designed to allow CFTR located at the cell surface to function correctly.

Why wasn't the Delta F508 mutation chosen for the Phase 2 VX-770 clinical trials?

Because G551D is already located at the cell surface, these patients have the greatest potential to benefit from treatment with VX-770."

This means, that if the CFTR was located at the cell surface, it might work for Delta F508. So, if we use the VX-809 and the VX-770, Delta F508s might have very good results, since...

"Vertex is also developing VX-809, known as a corrector, which is designed to move defective CFTR to its proper place in the cell."

*In other words, VX-809 should move the CFTR to the cell surface and VX-770 should correct the CFTR at the cell surface.*

<a target=_blank class=ftalternatingbarlinklarge href="http://www.cff.org/research/ClinicalResearch/FAQs/VX-770/">http://www.cff.org/research/Cl...lResearch/FAQs/VX-770/</a>
 
J

Jeana

New member
Actually, they are doing a clinical trial to see if it works on Delta F508, as well. Our clinic is participating.

According to the CFF website:

"VX-770, the most advanced of the two compounds, is known as a potentiator and is designed to allow CFTR located at the cell surface to function correctly.

Why wasn't the Delta F508 mutation chosen for the Phase 2 VX-770 clinical trials?

Because G551D is already located at the cell surface, these patients have the greatest potential to benefit from treatment with VX-770."

This means, that if the CFTR was located at the cell surface, it might work for Delta F508. So, if we use the VX-809 and the VX-770, Delta F508s might have very good results, since...

"Vertex is also developing VX-809, known as a corrector, which is designed to move defective CFTR to its proper place in the cell."

*In other words, VX-809 should move the CFTR to the cell surface and VX-770 should correct the CFTR at the cell surface.*

<a target=_blank class=ftalternatingbarlinklarge href="http://www.cff.org/research/ClinicalResearch/FAQs/VX-770/">http://www.cff.org/research/Cl...lResearch/FAQs/VX-770/</a>
 
J

Jeana

New member
Actually, they are doing a clinical trial to see if it works on Delta F508, as well. Our clinic is participating.

According to the CFF website:

"VX-770, the most advanced of the two compounds, is known as a potentiator and is designed to allow CFTR located at the cell surface to function correctly.

Why wasn't the Delta F508 mutation chosen for the Phase 2 VX-770 clinical trials?

Because G551D is already located at the cell surface, these patients have the greatest potential to benefit from treatment with VX-770."

This means, that if the CFTR was located at the cell surface, it might work for Delta F508. So, if we use the VX-809 and the VX-770, Delta F508s might have very good results, since...

"Vertex is also developing VX-809, known as a corrector, which is designed to move defective CFTR to its proper place in the cell."

*In other words, VX-809 should move the CFTR to the cell surface and VX-770 should correct the CFTR at the cell surface.*

<a target=_blank class=ftalternatingbarlinklarge href="http://www.cff.org/research/ClinicalResearch/FAQs/VX-770/">http://www.cff.org/research/Cl...lResearch/FAQs/VX-770/</a>
 
J

Jeana

New member
Actually, they are doing a clinical trial to see if it works on Delta F508, as well. Our clinic is participating.
<br />
<br />According to the CFF website:
<br />
<br />"VX-770, the most advanced of the two compounds, is known as a potentiator and is designed to allow CFTR located at the cell surface to function correctly.
<br />
<br />Why wasn't the Delta F508 mutation chosen for the Phase 2 VX-770 clinical trials?
<br />
<br />Because G551D is already located at the cell surface, these patients have the greatest potential to benefit from treatment with VX-770."
<br />
<br />This means, that if the CFTR was located at the cell surface, it might work for Delta F508. So, if we use the VX-809 and the VX-770, Delta F508s might have very good results, since...
<br />
<br />"Vertex is also developing VX-809, known as a corrector, which is designed to move defective CFTR to its proper place in the cell."
<br />
<br />*In other words, VX-809 should move the CFTR to the cell surface and VX-770 should correct the CFTR at the cell surface.*
<br />
<br /><a target=_blank class=ftalternatingbarlinklarge href="http://www.cff.org/research/ClinicalResearch/FAQs/VX-770/">http://www.cff.org/research/Cl...lResearch/FAQs/VX-770/</a>
 
You must log in or register to reply here.
Top